Pharmacological profile of the novel putative anxiolytic agent 1-amino-5-bromouracil.

doi:10.1002/chin.199429298

Paper

Pharmacological profile of the novel putative anxiolytic agent 1-amino-5-bromouracil.

Published Mar 1, 1994 · M. Imaizumi, S. Miyazaki, Y. Watanabe

Arzneimittel-Forschung

UNKNOWN SJR score

3

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

The newly synthesized compound, 1-amino-5-bromouracil (ABU, CAS 127984-93-4), showed unique anxiolytic activity in rats and mice. Its minimum effective dose was 10 mg/kg p.o. in the Geller type conflict test in rats, and it showed anxiolytic activity at a dose of 20 mg/kg i.p. in the Vogel type conflict test in mice. ABU also induced loss of the righting reflex in mice. The ED50, a dose level that induces loss of the righting reflex in 50% of mice, was 86.4 mg/kg p.o. On the other hand, ABU showed only weak activities both potentiating the drug-induced anesthesia and myorelaxing in comparison with diazepam. Furthermore ABU did not show an affinity for benzodiazepine receptor. Thus, the pharmacological profile of ABU is concluded to be different from that of diazepam.

Non-RCT

Animal Study

Study Snapshot

The novel anxiolytic agent 1-amino-5-bromouracil (ABU) shows unique anxiolytic activity in rats and mice, but has weak effects on drug-induced anesthesia and myorelaxing compared to diazepam.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Pharmacological profile of the novel putative anxiolytic agent 1-amino-5-bromouracil.

Sign up to use Study Snapshot

References

Citations